Tests semaglutide with usual care for atrial fibrillation in adults with obesity
Tests semaglutide, a weight loss drug, with usual care in adults with obesity.
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago and Phoenix, United StatesSee the 2 sites
- Trial code
- Registry title
- Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 200 people, planned
- Started
- 14 Apr 2025
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Semaglutide
- Placebo
- Record updated
- 14 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-75 with obesity and atrial fibrillation (AF). It tests whether semaglutide added to standard AF care changes AF and the chance it comes back.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Paroxysmal AF or persistent AF, with BMI of 30 kg/m2 or more. Catheter ablation for AF is either expected within 1 year or not expected within 1 year. People with type 2 diabetes can join if HbA1c is 10 % (86 mmol/mol) or less.
- Earlier treatment
- Must not have used a GLP-1 RA, a DPP4-inhibitor or an antiobesity medicine now or in the last 90 days. Must not have had bariatric surgery. People with type 2 diabetes on SGLT2-inhibitors or TZDs need a stable dose for at least 6 months.
Main reasons for not taking part
- Type 1 diabetes or current use of prandial insulin
- Active cancer, or chronic pancreatitis, or acute pancreatitis in the last 180 days
- Chronic kidney disease stage 4 (GFR below 30 ml/min)
- Personal or family history of medullary thyroid carcinoma or MEN 2
- Pregnant, breast-feeding or planning pregnancy
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Age 18-75 years
- BMI greater than or equal to 30 kg/m2
- Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)
- Ability to provide informed consent before any trial-related activities
- Patients with type 2 diabetes mellitus (T2DM) will be included:; If HbA1c (glycated hemoglobin) is less than or equal to 10 %; If the subject is taking basal insulin only or oral hypoglycemic agents or a combination of those; Patients on SGLT2-inhibitors and TZDs (Thiazolidinedione) will be included if they have been on a stable dose of these medications for at least 6 months; The following protocol will be adopted to adjust insulin secretagogues (sulfonylureas or meglitinides) and insulin during the study (adapted from the Look Ahead Study); Patients will be asked to check their blood glucose (BG) 4 x day (before meals and at bed time) during the dose escalation and dose stabilization phases (weeks 0 to 20) and recommendation of dose adjustments will be immediately sent to their treating physician according to the dose adjustment scale below:
- 2 blood sugars <100 mg/dl- reduce meds [insulin secretagogues (sulfonylureas or meglitinides) and basal insulin] by 0-50 %
- 3 blood sugars 80-100 mg/dl- reduce meds [insulin secretagogues (sulfonylureas or meglitinides) and basal insulin] by 25-75%
- 3 blood sugars <80 mg/dl > 2 x week or severe hypoglycemia or symptomatic hypoglycemia- reduce meds [insulin secretagogues (sulfonylureas or meglitinides) and basal insulin] by 50-100 %; Randomization to treatment (active and placebo) will be stratified to balance patients with T2DM across the study arms. After completion of the trial a prespecified subgroup analysis of the patients enrolled affected by T2DM will be performed; For women of child-bearing potential, use of appropriate contraception will be required; In patients that are prescribed amiodarone, standard care practices will be implemented to evaluate for liver and thyroid side effects with baseline liver and thyroid function tests via blood draw and evaluation every 6 months
Who cannot take part
- Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening
- Current antiobesity medication use or use within the last 90 days prior to screening
- A self-reported change in body weight of > 5 kg (11 lb.) within 30 days before screening
- Hospitalization for unstable angina, or TIA (Transient ischemic attack) < 30 days prior to screening
- Pulmonary embolism < 90 days before screening
- MI (myocardial infarction), stroke, etc. < 90 months prior to screening
- The receipt of any investigational drug within 90 days prior to this trial
- Acute pancreatitis < 180 days before screening
- A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY
- Previous participation in this trial (received at least one dose of study drug or placebo)
- History of bariatric surgery
- History of type I diabetes mellitus
- Uncontrolled thyroid disease: TSH (Thyroid-stimulating hormone) > 10.0 mIU/L (Milli-international Units Per Liter) or < 0.4 mIU/L (Milli-international Units Per Liter) at screening
- Active malignancy
- A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Chronic inflammatory conditions requiring immunosuppression and/or on glucocorticoids
- CKD (Chronic Kidney Disease) stage 4 (GFR <30 ml/min)
- Current use of prandial insulin
- Active enrollment in another investigational study that includes any kind of intervention
- Inability to comply with study procedures
- History or presence of chronic pancreatitis
- Pregnant, breast-feeding or planning pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of ChicagoChicago, United StatesContact: Silvana Pannain, MDTaking people
- The University of Arizona College of Medicine- PhoenixPhoenix, United StatesContact: Roderick Tung, MDNot yet recruiting
About the trial
What the trial wants to find out
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
The 2 groups in the trial
- SemaglutideExisting treatment, for comparison
Participants will have a 2 in 3 chance of receiving semaglutide (2.4 mg).
- PlaceboPlacebo, for comparison
Participants will have a 1 in 3 chance of receiving placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- Plain-language title
- Tests semaglutide with usual care for atrial fibrillation in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06499857, who can take part
- Record updated
- 14 November 2025